CardioPulmonary Resuscitation With Argon (CPAr) Trial

Launched by MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH · Jul 28, 2022

Keywords

ClinConnect Summary

The CardioPulmonary Resuscitation with Argon (CPAr) Trial is studying the use of argon, a gas that may help protect the brain and heart after a cardiac arrest. Researchers believe that using argon in combination with oxygen during ventilation after resuscitation can improve recovery and reduce brain and heart damage. This trial is important because it aims to see if this approach is safe and effective for patients who have been resuscitated from cardiac arrest outside of the hospital.

To be eligible for this trial, participants must be at least 18 years old and have experienced a witnessed cardiac arrest that was not caused by trauma, with a specific type of heart rhythm that can be treated. They should also be unconscious after their heart has started beating again and need to receive the study treatment within four hours of regaining circulation. If eligible, participants can expect to receive the argon/oxygen ventilation and will be monitored closely for their recovery. It's also worth noting that this study is currently recruiting participants, so there may be opportunities for eligible individuals to take part.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ICU admission after resuscitation from witnessed non-traumatic out-of-hospital cardiac arrest (OHCA) of presumably cardiac etiology with a presenting shockable rhythm;
• • age ≥ 18 years;
• • unconsciousness after return of spontaneous circulation (ROSC);
• • duration of CPR ≤ 40 mins;
• • initiation of study intervention ≤ 4 hrs from ROSC;
• • stable SaO2 ≥ 94% with a FiO2 of 30%.
• Exclusion Criteria:
• • Non-witnessed CA;
• • CA of traumatic origin or from a non-presumably cardiac cause;
• • CA with a non-shockable presenting rhythm (pulseless electrical activity and asystole);
• • female of childbearing potential defined as younger of 50 years;
• • pregnancy;
• • known terminal illness;
• • pre-CA cerebral performance category (CPC) ≥ 3;
• • initiation of the study intervention \> 4 hrs from ROSC;
• • participation to another clinical trial